Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Pediatric Drugs
Erschienen in: Pediatric Drugs 2/2012

01.04.2012 | Review Article

Gastroesophageal Reflux Disease in Children and Adolescents

When and How to Treat

verfasst von: Matthew W. Carroll, Dr Kevan Jacobson

Erschienen in: Pediatric Drugs | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Gastroesophageal reflux (GER) is a common presenting complaint in children and adults, and is a frequent reason for physician consultation. GER disease (GERD), whilst benign in the majority of cases, is frequently a chronic condition that has been shown to result in significantly reduced quality of life in children and adolescents. Furthermore, there is emerging evidence that the prevalence of GERD is rising and may have links to adult obesity and other morbidities. Consequently, accurate diagnosis, appropriate management strategies, and timely referral to specialist services are important principles in the effective management of GERD. Acid-suppressive drugs are effective therapies but are one of the most costly classes of drugs prescribed. Therefore, not only is an accurate diagnosis important to the patient, but it is also of significant interest from a public health and resource utilization standpoint.
Literatur
1.
Nelson SP, Chen EH, Syniar GM, et al. Prevalence of symptoms of gastro-esophageal reflux during infancy: a pediatric practice-based survey. Pediatric Practice Research Group. Arch Pediatr Adolesc Med 1997 Jun; 151(6): 569–72PubMedCrossRef
2.
Nelson SP, Kothari S, Wu EQ, et al. Pediatric gastroesophageal reflux disease and acid-related conditions: trends in incidence of diagnosis and acid suppression therapy. J Med Econ 2009; 12(4): 348–55PubMedCrossRef
3.
Nelson SP, Chen EH, Syniar GM, et al. Prevalence of symptoms of gastroesophageal reflux during childhood: a pediatric practice-based survey. Pediatric Practice Research Group. Arch Pediatr Adolesc Med 2000 Feb; 154(2): 150–4PubMed
4.
Vakil N. Disease definition, clinical manifestations, epidemiology and natural history of GERD. Best Pract Res Clin Gastroenterol 2010 Dec; 24(6): 759–64PubMedCrossRef
5.
Barak N, Ehrenpreis ED, Harrison JR, et al. Gastro-oesophageal reflux disease in obesity: pathophysiological and therapeutic considerations. Obes Rev 2002 Feb; 3(1): 9–15PubMedCrossRef
6.
Hollingworth S, Duncan EL, Martin JH. Marked increase in proton pump inhibitors use in australia. Pharmacoepidemiol Drug Saf 2010 Oct; 19(10): 1019–24PubMedCrossRef
7.
Sherman PM, Hassall E, Fagundes-Neto U, et al. A global, evidence-based consensus on the definition of gastroesophageal reflux disease in the pediatric population. Am J Gastroenterol 2009 May; 104(5): 1278–95PubMedCrossRef
8.
Martin AJ, Pratt N, Kennedy JD, et al. Natural history and familial relationships of infant spilling to 9 years of age. Pediatrics 2002 Jun; 109(6): 1061–7PubMedCrossRef
9.
Gold BD. Review article: epidemiology and management of gastro-oesophageal reflux in children. Aliment Pharmacol Ther 2004 Feb; 19Suppl. 1: 22–7PubMedCrossRef
10.
Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Global Consensus Group. Am J Gastroenterol 2006 Aug; 101(8): 1900–20PubMedCrossRef
11.
Orlando RC. Overview of the mechanisms of gastroesophageal reflux. Am J Med 2001 Dec 3; 111Suppl. 8A: 174–7SCrossRef
12.
Vandenplas Y, Rudolph CD, Di Lorenzo C, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr 2009 Oct; 49(4): 498–547PubMedCrossRef
13.
Mosby I. Mosby’s medical dictionary. 8th ed. St Louis (MO): Mosby/Elsevier, 2009
14.
Harnett KM, Cao W, Biancani P. Signal-transduction pathways that regulate smooth muscle function I: signal transduction in phasic (esophageal) and tonic (gastroesophageal sphincter) smooth muscles. Am J Physiol Gastrointest Liver Physiol 2005 Mar; 288(3): G407–16PubMedCrossRef
15.
Mittal RK, Holloway RH, Penagini R, et al. Transient lower esophageal sphincter relaxation. Gastroenterology 1995 Aug; 109(2): 601–10PubMedCrossRef
16.
Kawahara H, Dent J, Davidson G. Mechanisms responsible for gastroesophageal reflux in children. Gastroenterology 1997; 113(2): 399–408PubMedCrossRef
17.
18.
Rieder F, Cheng L, Harnett KM, et al. Gastroesophageal reflux disease-associated esophagitis induces endogenous cytokine production leading to motor abnormalities. Gastroenterology 2007 Jan; 132(1): 154–65PubMedCrossRef
19.
Cheng L, Harnett KM, Cao W, et al. Hydrogen peroxide reduces lower esophageal sphincter tone in human esophagitis. Gastroenterology 2005 Nov; 129(5): 1675–85PubMedCrossRef
20.
Rieder F, Biancani P, Harnett K, et al. Inflammatory mediators in gastroesophageal reflux disease: impact on esophageal motility, fibrosis, and carcinogenesis. Am J Physiol Gastrointest Liver Physiol 2010 May; 298(5): G571–81PubMedCrossRef
21.
Harnett KM, Rieder F, Behar J, et al. Viewpoints on acid-induced inflammatory mediators in esophageal mucosa. J Neurogastroenterol Motil 2010 Oct; 16(4): 374–88PubMedCrossRef
22.
Dodds WJ, Dent J, Hogan WJ, et al. Mechanisms of gastroesophageal reflux in patients with reflux esophagitis. N Engl J Med 1982 Dec 16; 307(25): 1547–52PubMedCrossRef
23.
Sloan S, Kahrilas PJ. Impairment of esophageal emptying with hiatal hernia. Gastroenterology 1991 Mar; 100(3): 596–605PubMed
24.
Fein M, Ritter MP, DeMeester TR, et al. Role of the lower esophageal sphincter and hiatal hernia in the pathogenesis of gastroesophageal reflux disease. J Gastrointest Surg 1999 Jul-Aug; 3(4): 405–10PubMedCrossRef
25.
Jones MP, Sloan SS, Rabine JC, et al. Hiatal hernia size is the dominant determinant of esophagitis presence and severity in gastroesophageal reflux disease. Am J Gastroenterol 2001 Jun; 96(6): 1711–7PubMedCrossRef
26.
Kahrilas PJ, Shi G, Manka M, et al. Increased frequency of transient lower esophageal sphincter relaxation induced by gastric distention in reflux patients with hiatal hernia. Gastroenterology 2000 Apr; 118(4): 688–95PubMedCrossRef
27.
Paterson WG, Kolyn DM. Esophageal shortening induced by short-term in-traluminal acid perfusion in opossum: a cause for hiatus hernia? Gastroenterology 1994 Dec; 107(6): 1736–40PubMed
28.
Dunne DP, Paterson WG. Acid-induced esophageal shortening in humans: a cause of hiatus hernia? Can J Gastroenterol 2000 Nov; 14(10): 847–50PubMed
29.
Paterson WG. Role of mast cell-derived mediators in acid-induced shortening of the esophagus. Am J Physiol 1998 Feb; 274 (2 Pt 1): G385–8PubMed
30.
Ruigómez A, Wallander M, Lundborg P, et al. Gastroesophageal reflux disease in children and adolescents in primary care. Scand J Gastroenterol 2010; 45(2): 139–46PubMedCrossRef
31.
von Baeyer CL, Spagrud LJ. Systematic review of observational (behavioral) measures of pain for children and adolescents aged 3 to 18 years. Pain 2007 Jan; 127(1-2): 140–50CrossRef
32.
Stanford EA, Chambers CT, Craig KD. A normative analysis of the development of pain-related vocabulary in children. Pain 2005 Mar; 114(1-2): 278–84PubMedCrossRef
33.
Stanford EA, Chambers CT, Craig KD. The role of developmental factors in predicting young children’s use of a self-report scale for pain. Pain 2006 Jan; 120(1-2): 16–23PubMedCrossRef
34.
Beyer JE, McGrath PJ, Berde CB. Discordance between self-report and behavioral pain measures in children aged 3–7 years after surgery. J Pain Symptom Manage 1990 Dec; 5(6): 350–6PubMedCrossRef
35.
Rasquin A, Di Lorenzo C, Forbes D, et al. Childhood functional gastrointestinal disorders: child/adolescent. Gastroenterology 2006 Apr; 130(5): 1527–37PubMedCrossRef
36.
Chang AB, Lasserson TJ, Kiljander TO, et al. Systematic review and meta-analysis of randomised controlled trials of gastro-oesophageal reflux interventions for chronic cough associated with gastro-oesophageal reflux. BMJ 2006 Jan 7; 332(7532): 11–7PubMedCrossRef
37.
Orenstein SR, Shalaby TM, Putnam PE. Thickened feedings as a cause of increased coughing when used as therapy for gastroesophageal reflux in infants. J Pediatr 1992 Dec; 121(6): 913–5PubMedCrossRef
38.
Vanderhoof JA, Moran JR, Harris CL, et al. Efficacy of a pre-thickened infant formula: a multicenter, double-blind, randomized, placebo-controlled parallel group trial in 104 infants with symptomatic gastroesophageal reflux. Clin Pediatr (Phila) 2003 Jul-Aug; 42(6): 483–95CrossRef
39.
Chang AB, Lasserson TJ, Gaffney J, et al. Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults. Cochrane Database Syst Rev 2005; (2): CD004823
40.
Chang AB, Lasserson TJ, Gaffney J, et al. Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults. Cochrane Database Syst Rev 2006; (4): CD004823
41.
Chang AB, Lasserson TJ, Gaffney J, et al. Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults. Cochrane Database Syst Rev 2011; (1): CD004823
42.
Vemulapalli R. Diet and lifestyle modifications in the management of gastroesophageal reflux disease. Nutr Clin Pract 2008 Jun-Jul; 23(3): 293–8PubMedCrossRef
43.
Festi D, Scaioli E, Baldi F, et al. Body weight, lifestyle, dietary habits and gastroesophageal reflux disease. World J Gastroenterol 2009 Apr 14; 15(14): 1690–701PubMedCrossRef
44.
Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med 2006 May 8; 166(9): 965–71PubMedCrossRef
45.
Tytgat GN, McColl K, Tack J, et al. New algorithm for the treatment of gastrooesophageal reflux disease. Aliment Pharmacol Ther 2008 Feb 1; 27(3): 249–56PubMedCrossRef
46.
Anand G, Katz PO. Gastroesophageal reflux disease and obesity. Gastroenterol Clin North Am 2010 Mar; 39(1): 39–46PubMedCrossRef
47.
Whiteman DC, Sadeghi S, Pandeya N, et al. Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus. Gut 2008 Feb; 57(2): 173–80PubMedCrossRef
48.
Smith KJ, O’Brien SM, Smithers BM, et al. Interactions among smoking, obesity, and symptoms of acid reflux in barrett’s esophagus. Cancer Epidemiol Biomarkers Prev 2005 Nov; 14 (11 Pt 1): 2481–6PubMedCrossRef
49.
Tighe MP, Afzal NA, Bevan A, et al. Current pharmacological management of gastro-esophageal reflux in children: an evidence-based systematic review. Paediatr Drugs 2009; 11(3): 185–202PubMedCrossRef
50.
51.
American Academy of Pediatrics, Committee on Nutrition. Aluminum toxicity in infants and children. Pediatrics 1996 Mar; 97(3): 413–6
52.
Friedman JA, Carroll JC, Bergstrom WH. Antacid-induced hypo-phosphatemic rickets. Drug Nutr Interact 1985; 3(4): 197–9PubMed
53.
Beall DP, Henslee HB, Webb HR, et al. Milk-alkali syndrome: a historical review and description of the modern version of the syndrome. Am J Med Sci 2006 May; 331(5): 233–42PubMedCrossRef
54.
Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997 Jun; 112(6): 1798–810PubMedCrossRef
55.
Chiba N. Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview. Can J Gastroenterol 1997 Sep; 11Suppl. B: 66–73B
56.
McCarty-Dawson D, Sue SO, Morrill B, et al. Ranitidine versus cimetidine in the healing of erosive esophagitis. Clin Ther 1996 Nov-Dec; 18(6): 1150–60PubMedCrossRef
57.
Cucchiara S, Franco MT, Terrin G, et al. Role of drug therapy in the treatment of gastro-oesophageal reflux disorder in children. Paediatr Drugs 2000 Jul-Aug; 2(4): 263–72PubMedCrossRef
58.
Khan M, Santana J, Donnellan C, et al. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev 2007; (2): CD003244
59.
van Pinxteren B, Numans ME, Bonis PA, et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2006; (3): CD002095
60.
Hyman PE, Garvey III TQ, Abrams CE. Tolerance to intravenous ranitidine. J Pediatr 1987 May; 110(5): 794–6PubMedCrossRef
61.
Sutphen JL, Dillard VL. Effect of ranitidine on twenty-four-hour gastric acidity in infants. J Pediatr 1989 Mar; 114(3): 472–4PubMedCrossRef
62.
Cucchiara S, Minella R, Iervolino C, et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Arch Dis Child 1993 Dec; 69(6): 655–9PubMedCrossRef
63.
Savarino V, Di Mario F, Scarpignato C. Proton pump inhibitors in GORD: an overview of their pharmacology, efficacy and safety. Pharmacol Res 2009 Mar; 59(3): 135–53PubMedCrossRef
64.
Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology 2000 Feb; 118 (2 Suppl. 1): S9–31PubMedCrossRef
65.
Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association medical position statement on the management of gastroesophageal reflux disease. Gastroenterology 2008 Oct; 135(4): 1383–91, 1391.e1–5PubMedCrossRef
66.
Israel DM, Hassall E. Omerprazole and other proton pump inhibitors: pharmacology, efficacy, and safety, with special reference to use in children. J Pediatr Gastroenterol Nutr 1998 Nov; 27(5): 568–79PubMedCrossRef
67.
Champion G, Richter JE, Vaezi MF, et al. Duodenogastroesophageal reflux: relationship to pH and importance in barrett’s esophagus. Gastroenterology 1994 Sep; 107(3): 747–54PubMedCrossRef
68.
Kearns GL, Winter HS. Proton pump inhibitors in pediatrics: relevant pharmacokinetics and pharmacodynamics. J Pediatr Gastroenterol Nutr 2003 Nov-Dec; 37Suppl. 1: S52–9PubMedCrossRef
69.
Kearns GL, Leeder JS, Gaedigk A. Impact of the CYP2C19*17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: evidence for a differential effect. Drug Metab Dispos 2010 Jun; 38(6): 894–7PubMedCrossRef
70.
Litalien C, Theoret Y, Faure C. Pharmacokinetics of proton pump inhibitors in children. Clin Pharmacokinet 2005; 44(5): 441–66PubMedCrossRef
71.
Zhao J, Li J, Hamer-Maansson JE, et al. Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. Clin Ther 2006 Nov; 28(11): 1868–76PubMedCrossRef
72.
Li J, Zhao J, Hamer-Maansson JE, et al. Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. Clin Ther 2006 Mar; 28(3): 419–27PubMedCrossRef
73.
Pettersen G, Mouksassi MS, Theoret Y, et al. Population pharmacokinetics of intravenous pantoprazole in paediatric intensive care patients. Br J Clin Pharmacol 2009 Feb; 67(2): 216–27PubMedCrossRef
74.
Ward RM, Kearns GL, Tammara B, et al. A multicenter, randomized, open-label, pharmacokinetics and safety study of pantoprazole tablets in children and adolescents aged 6 through 16 years with gastroesophageal reflux disease. J Clin Pharmacol 2010 Sep 17; 51(6): 876–87PubMedCrossRef
75.
Tolia V, Fitzgerald J, Hassall E, et al. Safety of lansoprazole in the treatment of gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr 2002; 35Suppl. 4: S300–7PubMedCrossRef
76.
Hassall E, Israel D, Shepherd R, et al. Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, toler-ability and dose requirements. International Pediatric Omeprazole Study Group. J Pediatr 2000 Dec; 137(6): 800–7PubMedCrossRef
77.
Orenstein SR, Hassall E. Infants and proton pump inhibitors: tribulations, no trials. J Pediatr Gastroenterol Nutr 2007 Oct; 45(4): 395–8PubMedCrossRef
78.
Nelis GF. Ranitidine in the management of gastro-oesophageal reflux disease. Neth J Med 1985; 28(5): 197–200PubMed
79.
Williams C, McColl KE. Review article: proton pump inhibitors and bacterial overgrowth. Aliment Pharmacol Ther 2006 Jan 1; 23(1): 3–10PubMedCrossRef
80.
Laheij RJ, Van Ijzendoorn MC, Janssen MJ, et al. Gastric acid-suppressive therapy and community-acquired respiratory infections. Aliment Pharmacol Ther 2003 Oct 15; 18(8): 847–51PubMedCrossRef
81.
Garcia Rodriguez LA, Ruigomez A, Panes J. Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol 2007 Dec; 5(12): 1418–23PubMedCrossRef
82.
Canani RB, Cirillo P, Roggero P, et al. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics 2006 May; 117(5): e817–20PubMedCrossRef
83.
Hassall E, Kerr W, El-Serag HB. Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration. J Pediatr 2007 Mar; 150(3): 262–7, 267.e1PubMedCrossRef
84.
Hibbs AM, Lorch SA. Metoclopramide for the treatment of gastroesophageal reflux disease in infants: a systematic review. Pediatrics 2006 Aug; 118(2): 746–52PubMedCrossRef
85.
Pritchard DS, Baber N, Stephenson T. Should domperidone be used for the treatment of gastro-oesophageal reflux in children? Systematic review of randomized controlled trials in children aged 1 month to 11 years old. Br J Clin Pharmacol 2005 Jun; 59(6): 725–9PubMedCrossRef
86.
Maclennan S, Augood C, Cash-Gibson L, et al. Cisapride treatment for gastro-oesophageal reflux in children. Cochrane Database Syst Rev 2010; (4): CD002300
87.
Rocha CM, Barbosa MM. QT interval prolongation associated with the oral use of domperidone in an infant. Pediatr Cardiol 2005 Sep-Oct; 26(5): 720–3PubMedCrossRef
88.
Mousa H, Caniano DA, Alhajj M, et al. Effect of nissen fundoplication on gastric motor and sensory functions. J Pediatr Gastroenterol Nutr 2006 Aug; 43(2): 185–9PubMedCrossRef
89.
Di Lorenzo C, Orenstein S. Fundoplication: friend or foe? J Pediatr Gastroenterol Nutr 2002 Feb; 34(2): 117–24PubMedCrossRef
90.
Diaz DM, Gibbons TE, Heiss K, et al. Antireflux surgery outcomes in pediatric gastroesophageal reflux disease. Am J Gastroenterol 2005 Aug; 100(8): 1844–52PubMedCrossRef
91.
Suwandhi E, Ton MN, Schwarz SM. Gastroesophageal reflux in infancy and childhood. Pediatr Ann 2006 Apr; 35(4): 259–66PubMed
92.
Hassall E. Outcomes of fundoplication: causes for concern, newer options. Arch Dis Child 2005 Oct; 90(10): 1047–52PubMedCrossRef
93.
Bjornsson E, Abrahamsson H, Simren M, et al. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2006 Sep 15; 24(6): 945–54PubMedCrossRef
94.
Fossmark R, Johnsen G, Johanessen E, et al. Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Aliment Pharmacol Ther 2005 Jan 15; 21(2): 149–54PubMedCrossRef
95.
Marlais M, Fishman JR, Koglmeier J, et al. Reduced quality of life in children with gastro-oesophageal reflux disease. Acta Paediatr 2010 Mar; 99(3): 418–21PubMedCrossRef
Metadaten
Titel
Gastroesophageal Reflux Disease in Children and Adolescents
When and How to Treat
verfasst von
Matthew W. Carroll
Dr Kevan Jacobson
Publikationsdatum
01.04.2012
Verlag
Springer International Publishing
Erschienen in
Pediatric Drugs / Ausgabe 2/2012
Print ISSN: 1174-5878
Elektronische ISSN: 1179-2019
DOI
https://doi.org/10.2165/11594360-000000000-00000

Weitere Artikel der Ausgabe 2/2012

Pediatric Drugs 2/2012 Zur Ausgabe

Review Article

Cryopyrin-Associated Periodic Syndromes

Review Article

Efficacy and Tolerability of Pharmacotherapies to Aid Smoking Cessation in Adolescents

Original Research Article

Safety and Tolerability of Loteprednol Etabonate 0.5% and Tobramycin 0.3% Ophthalmic Suspension in Pediatric Subjects

Therapy in Practice

Medical Management of Nocturnal Enuresis

Adis Drug Profile

Atazanavir

Neu im Fachgebiet Pädiatrie

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

16.05.2024 Arterielle Hypertonie in der Pädiatrie Nachrichten

Wie wichtig es ist, pädiatrische Patienten auf Bluthochdruck zu screenen, zeigt eine kanadische Studie: Hypertone Druckwerte in Kindheit und Jugend steigern das Risiko für spätere kardiovaskuläre Komplikationen.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise